Primary Immunodeficiency Diseases clinical trials at University of California Health

6 in progress, 4 open to eligible people

Showing trials for

  • Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

    open to eligible people ages 1 month to 79 years

    Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

    at UCLA UCSF

  • EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

    open to eligible people ages 1 month to 79 years

    Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

    at UCLA UCSF

  • Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

    open to eligible people ages 1 month to 79 years

    BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be safe and effective in decreasing specific viral load in children, adolescents and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).

    at UCSF

  • Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

    open to eligible people ages 1 month to 79 years

    CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

    at UCSF

  • About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

    Sorry, in progress, not accepting new patients

    The main aim of this study is to compare the pharmacokinetics (PK) of subcutaneous (SC) administration of TAK-881 with HYQVIA in participants with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The participants who are already receiving intravenous immunoglobulin G (IGIV)/conventional subcutaneous intravenous immunoglobulin G (cIGSC) will be treated with HYQVIA or TAK-881 with the same dose and dosing interval of immunoglobulin for up to 24 weeks. Participants will need to visit the clinic every 3 or 4 weeks during the duration of the study.

    at UC Irvine

  • Tabelecleucel in Participants with Epstein-barr Virus-associated Diseases

    Sorry, not currently recruiting here

    The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with Epstein-Barr virus (EBV) associated diseases.

    at UC Davis UCLA

Our lead scientists for Primary Immunodeficiency Diseases research studies include .

Last updated: